tiprankstipranks
Trending News
More News >
Merck KGaA (DE:MRK)
XETRA:MRK
Advertisement

Merck KGaA (MRK) AI Stock Analysis

Compare
148 Followers

Top Page

DE:MRK

Merck KGaA

(XETRA:MRK)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 4o)
Rating:68Neutral
Price Target:
€125.00
▲(8.46% Upside)
Merck KGaA's overall stock score is driven by its strong financial performance and stable valuation. The technical analysis suggests a cautiously optimistic outlook, with short-term bullish momentum. The absence of earnings call data and corporate events means the score is primarily based on financial and technical factors.
Positive Factors
Strong Profitability
High profitability margins indicate efficient operations and pricing power, supporting long-term financial stability and reinvestment capacity.
Stable Capital Structure
A stable capital structure with low leverage enhances financial resilience, providing flexibility for strategic investments and growth initiatives.
Solid Cash Generation
Consistent cash generation from operations supports liquidity and the ability to fund ongoing business activities and strategic projects.
Negative Factors
Declining Revenue Growth
Negative revenue growth suggests challenges in market expansion or product demand, which could impact long-term competitive positioning and profitability.
Decreased Free Cash Flow
Reduced free cash flow growth may limit the company's ability to invest in new opportunities and manage debt, affecting future financial flexibility.
Need for Enhanced Profitability
A declining return on equity indicates potential inefficiencies or competitive pressures, necessitating improved operational strategies to sustain investor returns.

Merck KGaA (MRK) vs. iShares MSCI Germany ETF (EWG)

Merck KGaA Business Overview & Revenue Model

Company DescriptionMerck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
How the Company Makes MoneyMerck KGaA generates revenue through several key streams. The healthcare segment is a major contributor, with sales from prescription drugs and biopharmaceuticals targeting various therapeutic areas. The life science sector provides laboratory supplies, reagents, and services for research and production processes, catering to academic institutions and industrial customers. The performance materials division specializes in providing high-tech materials for the electronics industry, including liquid crystals and pigments. Strategic partnerships and collaborations with biotech firms and research institutions enhance Merck's innovation capabilities and market reach, contributing significantly to its earnings. Additionally, investment in R&D fosters the development of new products, which can lead to increased sales and market share.

Merck KGaA Financial Statement Overview

Summary
Merck KGaA demonstrates strong profitability with healthy EBIT and EBITDA margins and a stable financial position. However, recent declines in revenue growth and free cash flow highlight areas for improvement, necessitating a focus on revenue generation and cash flow management.
Income Statement
75
Positive
Merck KGaA's income statement shows strong profitability with a consistent gross profit margin around 59% and a net profit margin over 13% in TTM. However, the revenue growth rate has been negative recently, indicating a potential challenge in maintaining top-line growth. Despite this, the EBIT and EBITDA margins remain healthy, reflecting operational efficiency.
Balance Sheet
70
Positive
The balance sheet is stable with a manageable debt-to-equity ratio of 0.29 in TTM, showing a decrease from previous years, which indicates improved leverage management. Return on equity is solid at around 9.67%, though slightly lower than previous years, suggesting a need for enhanced profitability. The equity ratio indicates a strong capital structure.
Cash Flow
68
Positive
Cash flow analysis reveals a decline in free cash flow growth, which is a concern for future liquidity. The operating cash flow to net income ratio is moderate, indicating reasonable cash generation from operations. However, the free cash flow to net income ratio has decreased, suggesting potential challenges in cash management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue21.22B21.16B20.99B22.23B19.69B17.53B
Gross Profit12.41B12.48B11.67B13.71B12.34B10.70B
EBITDA5.87B5.96B5.68B6.28B5.88B4.78B
Net Income2.86B2.78B2.82B3.33B3.06B1.99B
Balance Sheet
Total Assets47.35B51.57B48.49B48.53B45.36B41.80B
Cash, Cash Equivalents and Short-Term Investments1.57B2.71B2.41B1.64B1.62B1.14B
Total Debt9.40B10.27B9.94B10.40B10.77B12.04B
Total Liabilities19.02B21.58B21.74B22.52B23.95B24.78B
Stockholders Equity28.26B29.91B26.68B25.93B21.34B16.95B
Cash Flow
Free Cash Flow1.78B2.40B1.76B2.45B3.19B1.91B
Operating Cash Flow3.81B4.59B3.78B4.26B4.62B3.48B
Investing Cash Flow-2.89B-3.05B-1.89B-2.74B-1.58B-1.34B
Financing Cash Flow-2.38B-985.00M-1.73B-1.55B-2.50B-1.52B

Merck KGaA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price115.25
Price Trends
50DMA
111.54
Positive
100DMA
111.39
Positive
200DMA
119.42
Negative
Market Momentum
MACD
0.92
Positive
RSI
53.42
Neutral
STOCH
59.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MRK, the sentiment is Positive. The current price of 115.25 is below the 20-day moving average (MA) of 115.39, above the 50-day MA of 111.54, and below the 200-day MA of 119.42, indicating a neutral trend. The MACD of 0.92 indicates Positive momentum. The RSI at 53.42 is Neutral, neither overbought nor oversold. The STOCH value of 59.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MRK.

Merck KGaA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$54.23B25.1011.75%1.92%5.85%16.20%
69
Neutral
€14.97B99.045.01%0.38%5.82%59.90%
69
Neutral
€26.92B24.527.30%2.07%-0.59%
68
Neutral
€50.06B17.5010.08%1.91%1.67%9.02%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
€1.31B64.150.11%-18.82%-113.85%
45
Neutral
€27.04B-7.93-10.35%0.40%-1.99%-169.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:MRK
Merck KGaA
115.25
-38.21
-24.90%
DE:BAYN
Bayer
27.58
1.95
7.63%
DE:BIO
Biotest
38.00
-3.60
-8.65%
DE:FRE
Fresenius SE & Co. KGaA
48.97
15.89
48.06%
DE:SRT
Sartorius
191.80
-1.78
-0.92%
DE:SHL
Siemens Healthineers AG
49.36
-1.11
-2.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 22, 2025